HLS Therapeutics Partners With Bayer to Commercialize Verquvo in Canada
HLS Therapeutics entered a partnership with Bayer to commercialize Verquvo in Canada.
Related stories
Nasdaq single-stock trading halt continues, symbol not given — reason not given (10:35 AM ET)
Nasdaq kept trading halted in a single listed security (reason not given) at 10:35 AM ET.
M impact | EQUITY | Nov 03, 2026, 03:52 PM UTC
Yum China Reports Quarterly Results Through September 30
M impact | EQUITY | Nov 03, 2026, 03:39 PM UTC
CVR Energy Shares Fall After Equity Offering for Refinery Acquisition
CVR Energy shares declined after it launched an equity offering to fund its acquisition of a Marathon refinery.
L impact | EQUITY | Nov 03, 2026, 03:38 PM UTC
S&P 500 and Nasdaq Edge Higher Ahead of Midterm Results; Apple Falls 2%
US stocks rose as crude oil prices fell ahead of midterm election results. Apple shares dropped 2% after its earnings failed to impress investors.
M impact | EQUITY | Nov 03, 2026, 03:38 PM UTC
Pfizer lifts full-year guidance after robust third-quarter results
Pfizer reported third-quarter revenue of $16.6 billion, largely unchanged from a year earlier. Excluding Comirnaty and Paxlovid, revenue grew 7% operationally.
M impact | EQUITY | Nov 03, 2026, 03:38 PM UTC
Meta Platforms Reportedly Targets Up to $25 Billion Bond Sale
Meta Platforms has reportedly launched an investment-grade bond sale, targeting up to $25 billion.
M impact | EQUITY | Nov 03, 2026, 03:37 PM UTC